{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T05:44:31Z","timestamp":1675403071538},"reference-count":14,"publisher":"American Diabetes Association","issue":"10","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,10,1]]},"DOI":"10.2337\/db13-0996","type":"journal-article","created":{"date-parts":[[2013,9,25]],"date-time":"2013-09-25T11:30:55Z","timestamp":1380108655000},"page":"e19-e22","update-policy":"http:\/\/dx.doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":8,"title":["Reponse to Comments on: Butler et al. Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors. Diabetes 2013;62:2595\u20132604"],"prefix":"10.2337","volume":"62","author":[{"given":"Alexandra E.","family":"Butler","sequence":"first","affiliation":[{"name":"Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha","family":"Campbell-Thompson","sequence":"additional","affiliation":[{"name":"Departments of Pathology and Pediatrics, College of Medicine, University of Florida, Gainesville, Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatyana","family":"Gurlo","sequence":"additional","affiliation":[{"name":"Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David W.","family":"Dawson","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Atkinson","sequence":"additional","affiliation":[{"name":"Departments of Pathology and Pediatrics, College of Medicine, University of Florida, Gainesville, Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter C.","family":"Butler","sequence":"additional","affiliation":[{"name":"Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1167","published-online":{"date-parts":[[2013,9,17]]},"reference":[{"key":"2022031211533933200_B1"},{"key":"2022031211533933200_B2"},{"key":"2022031211533933200_B3","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.2337\/db12-1686","article-title":"Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors","volume":"62","author":"Butler","year":"2013","journal-title":"Diabetes"},{"key":"2022031211533933200_B4","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.4158\/EP11264.CR","article-title":"Case report of acute necrotizing pancreatitis associated with combination treatment of sitagliptin and exenatide","volume":"18","author":"Iyer","year":"2012","journal-title":"Endocr Pract"},{"key":"2022031211533933200_B5","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.2337\/diabetes.48.12.2270","article-title":"Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats","volume":"48","author":"Xu","year":"1999","journal-title":"Diabetes"},{"key":"2022031211533933200_B6","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1172\/JCI20911","article-title":"Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors","volume":"113","author":"Sloop","year":"2004","journal-title":"J Clin Invest"},{"key":"2022031211533933200_B7","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.2337\/dc10-0373","article-title":"The presence of GAD and IA-2 antibodies in youth with a type 2 diabetes phenotype: results from the TODAY study","volume":"33","author":"Klingensmith","year":"2010","journal-title":"Diabetes Care"},{"key":"2022031211533933200_B8","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1001\/jama.2012.15008","article-title":"Pancreas organ weight in individuals with disease-associated autoantibodies at risk for type 1 diabetes","volume":"308","author":"Campbell-Thompson","year":"2012","journal-title":"JAMA"},{"key":"2022031211533933200_B9","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/ca.20543","article-title":"Pancreas volumes in humans from birth to age one hundred taking into account sex, obesity, and presence of type-2 diabetes","volume":"20","author":"Saisho","year":"2007","journal-title":"Clin Anat"},{"key":"2022031211533933200_B10","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.2337\/dc12-2713","article-title":"A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe?","volume":"36","author":"Butler","year":"2013","journal-title":"Diabetes Care"},{"key":"2022031211533933200_B11","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/ncpendmet0641","article-title":"Diabetic ketoacidosis in type 2 diabetes mellitus\u2014pathophysiology and clinical presentation","volume":"3","author":"Davis","year":"2007","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"2022031211533933200_B12","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s11892-012-0334-z","article-title":"Current treatment options for type 2 diabetes mellitus in youth: today\u2019s realities and lessons from the TODAY study","volume":"13","author":"George","year":"2013","journal-title":"Curr Diab Rep"},{"key":"2022031211533933200_B13","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.2337\/db11-1109","article-title":"Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model","volume":"61","author":"Gier","year":"2012","journal-title":"Diabetes"},{"key":"2022031211533933200_B14","doi-asserted-by":"crossref","first-page":"f3680","DOI":"10.1136\/bmj.f3680","article-title":"Has pancreatic damage from glucagon suppressing diabetes drugs been underplayed?","volume":"346","author":"Cohen","year":"2013","journal-title":"BMJ"}],"container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.org\/diabetes\/diabetes\/article-pdf\/62\/10\/e19\/570731\/e19.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/62\/10\/e19\/570731\/e19.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T16:37:51Z","timestamp":1667407071000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/62\/10\/e19\/18018\/Reponse-to-Comments-on-Butler-et-al-Marked"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,17]]},"references-count":14,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2013,9,17]]},"published-print":{"date-parts":[[2013,10,1]]}},"URL":"https:\/\/doi.org\/10.2337\/db13-0996","relation":{},"ISSN":["0012-1797","1939-327X"],"issn-type":[{"value":"0012-1797","type":"print"},{"value":"1939-327X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,17]]}}}